2 terminated, 1 unknown. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
Follow TcLand Expression S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis Infliximab, Adalimumab, Etanercept - RheumatoId Arthritis | Terminated | TcLand Expression S.A. | 250 | 2016-12-01 | 2019-12-24 | |
| Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy Rheumatoid Arthritis | Terminated | TcLand Expression S.A. | 123 | 2011-02-01 | 2013-02-01 | |
| Assessment Of the Safety and Benefit of Prospective Immunosuppressive Drug Withdrawal in Liver Transplantation and Prediction of Operational Tolerance Gradual immunosuppression drug withdrawal - Liver Transplantation | Phase 2 | Unknown | Hospital Clinic of Barcelona | 80 | 2005-11-01 | 2011-04-20 |
Adalimumab (1) · CT-P13 (1) · Certolizumab Pegol (1) · Etanercept (1) · Infliximab (1) · etanercept biosimilar SB4 (1) · golimumab (1)
France (2) · Spain (2) · Canada (1) · Czechia (1) · Hungary (1) · Israel (1) · Italy (1) · Lithuania (1) · Netherlands (1) · Romania (1) · Slovakia (1) · Turkey (Türkiye) (1)
Alberto Sanchez-Fueyo, MD (1) · Giuseppe Tisone, MD (1) · Jacques Pirenne, MD (1)